Open Access Peer-reviewed

An Altered Drug Resistance Pattern in Salmonella Typhi

Devindra Sehra1,, Sudhish Sehra2, Pooja Relia3, Shiv Tej Sehra4

1Senior Consultant Medicine, Maharaja Agrasen Hospital, New Delhi

2Senior Consultant Medicine, Balaji Action Hospital, New Delhi

3Consultant Medicine, Maharaja Agrasen Hospital, New Delhi

4Fellow, USA

American Journal of Infectious Diseases and Microbiology. 2013, 1(5), 84-85. DOI: 10.12691/ajidm-1-5-1
Published online: August 25, 2017


Enteric fever is an endemic disease in the tropics and subtropical region. It is caused by the bacterium Salmonella typhi. It is a systemic disease and occurs by ingestion of infected food or water usually from a feco-oral source. It is primarily found in developing countries where sanitary conditions are poor . Despite the emergence of newer antibacterial drugs, enteric fever has continued to be a major health problem. S. typhi bacterium has gained resistance to antibiotics like ampicillin, ceftriaxone and cotrimoxazole, besides developing resistance to previously efficacious drugs like ciprofloxacin . The emergence of multidrug resistance to the commonly used antibiotics has further complicated the treatment and management of enteric fever and this is recognized as one of the greatest challenges in the management of the disease . Resistance to various antibiotics has been previously reported in Salmonella typhi. However, to the best of our knowledge, a strain that is resistant to 3rd generation cephalosporins, as well as commonly used fluoroquinolones but sensitive to chloramphenicol has not been identified yet. In this case report, we provide evidence of such a strain and its successful resolution through the use of chloramphenicol.


enteric fever, chloramphenicol, anti-microbial resistance, anti-bacterial drugs
[1]  World Health Organization (WHO), prepared for World Water Day 2001. Reviwed by Staff and Experts from the Cluster on Commuicable Disease (CDS) and the Water, Sanitation and Health Unit (WSH), World Health Organization (WHO), 2008.
[2]  World Health Organization, Typhoid Vaccine (Initiative for Vaccine Research), WHO, Genevas, Switzerland, 2010.
[3]  T. Butt, R.N. Ahmad, A. Mahmood and S. Zaidi, Ciprofloxacin treatment failure in typhoid fever case, Pakistan, Emerging Infectious Diseases, vol. 9, no. 12, p. 1621-1622, 2003.View Article  PubMed
[4]  A.S. Dajani, Beta-Lactam resistance: minimizing the risk of therapy failure. The Journal of International Medical Research, vol30,supplement 1 p p. 1A-33A, 2002.
[5]  Arora D, Singh R Kaul M, Ami Rao, A changing pattern in AMS of Salmonella typhi in North India. African Journal of Microbiol Research 2010;4(3); 197-203.
[6]  Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis. 1997 Jan;24 Suppl 1:S106-9.View Article  PubMed
[7]  Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med. 2002 Nov 28;347(22):1770-82.View Article  PubMed
[8]  Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O'Brien TF, Pablos-Mendez A, Klugman KP. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis. 2005 Aug;5(8):481-93.View Article
[9]  Thaver D, Zaidi AK, Critchley JA, Azmatullah A, Madni SA, Bhutta ZA. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev. 2008(4):CD004530. PubMed